Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network.
Identifieur interne : 000296 ( PubMed/Curation ); précédent : 000295; suivant : 000297Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network.
Auteurs : James G. Carlucci [États-Unis] ; Meridith Blevins Peratikos ; Aaron M. Kipp ; Mary L. Lindegren ; Quy T. Du ; Lorna Renner ; Gary Reubenson ; John Ssali ; Marcel Yotebieng ; Anna M. Mandalakas ; Mary-Ann Davies ; Marie Ballif ; Lukas Fenner ; April C. PettitSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
Descripteurs français
- KwdFr :
- Afrique subsaharienne (épidémiologie), Agents antiVIH (usage thérapeutique), Antituberculeux (usage thérapeutique), Asie du Sud-Est (épidémiologie), Bases de données factuelles, Charge virale, Co-infection (traitement médicamenteux), Co-infection (épidémiologie), Enfant, Enfant d'âge préscolaire, Femelle, Humains, Infections à VIH (traitement médicamenteux), Infections à VIH (épidémiologie), Modèles de hasards proportionnels, Mâle, Nourrisson, Numération des lymphocytes CD4, Organisation mondiale de la santé, Résultat thérapeutique, Tuberculose (traitement médicamenteux), Tuberculose (épidémiologie), Études rétrospectives.
- MESH :
- traitement médicamenteux : Co-infection, Infections à VIH, Tuberculose.
- usage thérapeutique : Agents antiVIH, Antituberculeux.
- épidémiologie : Afrique subsaharienne, Asie du Sud-Est, Co-infection, Infections à VIH, Tuberculose.
- Bases de données factuelles, Charge virale, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Modèles de hasards proportionnels, Mâle, Nourrisson, Numération des lymphocytes CD4, Organisation mondiale de la santé, Résultat thérapeutique, Études rétrospectives.
English descriptors
- KwdEn :
- Africa South of the Sahara (epidemiology), Anti-HIV Agents (therapeutic use), Antitubercular Agents (therapeutic use), Asia, Southeastern (epidemiology), CD4 Lymphocyte Count, Child, Child, Preschool, Coinfection (drug therapy), Coinfection (epidemiology), Databases, Factual, Female, HIV Infections (drug therapy), HIV Infections (epidemiology), Humans, Infant, Male, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Tuberculosis (drug therapy), Tuberculosis (epidemiology), Viral Load, World Health Organization.
- MESH :
- chemical , therapeutic use : Anti-HIV Agents, Antitubercular Agents.
- drug therapy : Coinfection, HIV Infections, Tuberculosis.
- epidemiology : Africa South of the Sahara, Asia, Southeastern, Coinfection, HIV Infections, Tuberculosis.
- CD4 Lymphocyte Count, Child, Child, Preschool, Databases, Factual, Female, Humans, Infant, Male, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Viral Load, World Health Organization.
Abstract
Management of tuberculosis (TB) is challenging in HIV/TB-coinfected children. The World Health Organization recommends nucleic acid amplification tests for TB diagnosis, a 4-drug regimen including ethambutol during intensive phase (IP) of treatment, and initiation of antiretroviral therapy (ART) within 8 weeks of TB diagnosis. We investigated TB treatment outcomes by diagnostic modality, IP regimen, and ART status.
DOI: 10.1097/QAI.0000000000001335
PubMed: 28234689
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000296
Links to Exploration step
pubmed:28234689Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network.</title><author><name sortKey="Carlucci, James G" sort="Carlucci, James G" uniqKey="Carlucci J" first="James G" last="Carlucci">James G. Carlucci</name><affiliation wicri:level="2"><nlm:affiliation>*Vanderbilt Institute for Global Health, Nashville, TN; †Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; ‡Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN; §Vanderbilt Tuberculosis Center, Nashville, TN; ‖Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ¶Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; #Children's Hospital 1, Ho Chi Minh City, Vietnam; **University of Ghana School of Medicine and Dentistry, Accra, Ghana; ††Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Masaka Regional Referral Hospital, Masaka, Uganda; §§The Ohio State University, College of Public Health, Columbus, OH; ‖‖Department of Pediatrics, Baylor College of Medicine, Houston, TX; ¶¶Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; ##Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; ***Swiss Tropical and Public Health Institute, Basel, Switzerland; †††University of Basel, Basel, Switzerland; and ‡‡‡Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>*Vanderbilt Institute for Global Health, Nashville, TN; †Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; ‡Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN; §Vanderbilt Tuberculosis Center, Nashville, TN; ‖Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ¶Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; #Children's Hospital 1, Ho Chi Minh City, Vietnam; **University of Ghana School of Medicine and Dentistry, Accra, Ghana; ††Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Masaka Regional Referral Hospital, Masaka, Uganda; §§The Ohio State University, College of Public Health, Columbus, OH; ‖‖Department of Pediatrics, Baylor College of Medicine, Houston, TX; ¶¶Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; ##Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; ***Swiss Tropical and Public Health Institute, Basel, Switzerland; †††University of Basel, Basel, Switzerland; and ‡‡‡Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Blevins Peratikos, Meridith" sort="Blevins Peratikos, Meridith" uniqKey="Blevins Peratikos M" first="Meridith" last="Blevins Peratikos">Meridith Blevins Peratikos</name></author><author><name sortKey="Kipp, Aaron M" sort="Kipp, Aaron M" uniqKey="Kipp A" first="Aaron M" last="Kipp">Aaron M. Kipp</name></author><author><name sortKey="Lindegren, Mary L" sort="Lindegren, Mary L" uniqKey="Lindegren M" first="Mary L" last="Lindegren">Mary L. Lindegren</name></author><author><name sortKey="Du, Quy T" sort="Du, Quy T" uniqKey="Du Q" first="Quy T" last="Du">Quy T. Du</name></author><author><name sortKey="Renner, Lorna" sort="Renner, Lorna" uniqKey="Renner L" first="Lorna" last="Renner">Lorna Renner</name></author><author><name sortKey="Reubenson, Gary" sort="Reubenson, Gary" uniqKey="Reubenson G" first="Gary" last="Reubenson">Gary Reubenson</name></author><author><name sortKey="Ssali, John" sort="Ssali, John" uniqKey="Ssali J" first="John" last="Ssali">John Ssali</name></author><author><name sortKey="Yotebieng, Marcel" sort="Yotebieng, Marcel" uniqKey="Yotebieng M" first="Marcel" last="Yotebieng">Marcel Yotebieng</name></author><author><name sortKey="Mandalakas, Anna M" sort="Mandalakas, Anna M" uniqKey="Mandalakas A" first="Anna M" last="Mandalakas">Anna M. Mandalakas</name></author><author><name sortKey="Davies, Mary Ann" sort="Davies, Mary Ann" uniqKey="Davies M" first="Mary-Ann" last="Davies">Mary-Ann Davies</name></author><author><name sortKey="Ballif, Marie" sort="Ballif, Marie" uniqKey="Ballif M" first="Marie" last="Ballif">Marie Ballif</name></author><author><name sortKey="Fenner, Lukas" sort="Fenner, Lukas" uniqKey="Fenner L" first="Lukas" last="Fenner">Lukas Fenner</name></author><author><name sortKey="Pettit, April C" sort="Pettit, April C" uniqKey="Pettit A" first="April C" last="Pettit">April C. Pettit</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28234689</idno><idno type="pmid">28234689</idno><idno type="doi">10.1097/QAI.0000000000001335</idno><idno type="wicri:Area/PubMed/Corpus">000296</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000296</idno><idno type="wicri:Area/PubMed/Curation">000296</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000296</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network.</title><author><name sortKey="Carlucci, James G" sort="Carlucci, James G" uniqKey="Carlucci J" first="James G" last="Carlucci">James G. Carlucci</name><affiliation wicri:level="2"><nlm:affiliation>*Vanderbilt Institute for Global Health, Nashville, TN; †Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; ‡Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN; §Vanderbilt Tuberculosis Center, Nashville, TN; ‖Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ¶Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; #Children's Hospital 1, Ho Chi Minh City, Vietnam; **University of Ghana School of Medicine and Dentistry, Accra, Ghana; ††Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Masaka Regional Referral Hospital, Masaka, Uganda; §§The Ohio State University, College of Public Health, Columbus, OH; ‖‖Department of Pediatrics, Baylor College of Medicine, Houston, TX; ¶¶Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; ##Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; ***Swiss Tropical and Public Health Institute, Basel, Switzerland; †††University of Basel, Basel, Switzerland; and ‡‡‡Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>*Vanderbilt Institute for Global Health, Nashville, TN; †Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; ‡Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN; §Vanderbilt Tuberculosis Center, Nashville, TN; ‖Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ¶Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; #Children's Hospital 1, Ho Chi Minh City, Vietnam; **University of Ghana School of Medicine and Dentistry, Accra, Ghana; ††Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Masaka Regional Referral Hospital, Masaka, Uganda; §§The Ohio State University, College of Public Health, Columbus, OH; ‖‖Department of Pediatrics, Baylor College of Medicine, Houston, TX; ¶¶Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; ##Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; ***Swiss Tropical and Public Health Institute, Basel, Switzerland; †††University of Basel, Basel, Switzerland; and ‡‡‡Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Blevins Peratikos, Meridith" sort="Blevins Peratikos, Meridith" uniqKey="Blevins Peratikos M" first="Meridith" last="Blevins Peratikos">Meridith Blevins Peratikos</name></author><author><name sortKey="Kipp, Aaron M" sort="Kipp, Aaron M" uniqKey="Kipp A" first="Aaron M" last="Kipp">Aaron M. Kipp</name></author><author><name sortKey="Lindegren, Mary L" sort="Lindegren, Mary L" uniqKey="Lindegren M" first="Mary L" last="Lindegren">Mary L. Lindegren</name></author><author><name sortKey="Du, Quy T" sort="Du, Quy T" uniqKey="Du Q" first="Quy T" last="Du">Quy T. Du</name></author><author><name sortKey="Renner, Lorna" sort="Renner, Lorna" uniqKey="Renner L" first="Lorna" last="Renner">Lorna Renner</name></author><author><name sortKey="Reubenson, Gary" sort="Reubenson, Gary" uniqKey="Reubenson G" first="Gary" last="Reubenson">Gary Reubenson</name></author><author><name sortKey="Ssali, John" sort="Ssali, John" uniqKey="Ssali J" first="John" last="Ssali">John Ssali</name></author><author><name sortKey="Yotebieng, Marcel" sort="Yotebieng, Marcel" uniqKey="Yotebieng M" first="Marcel" last="Yotebieng">Marcel Yotebieng</name></author><author><name sortKey="Mandalakas, Anna M" sort="Mandalakas, Anna M" uniqKey="Mandalakas A" first="Anna M" last="Mandalakas">Anna M. Mandalakas</name></author><author><name sortKey="Davies, Mary Ann" sort="Davies, Mary Ann" uniqKey="Davies M" first="Mary-Ann" last="Davies">Mary-Ann Davies</name></author><author><name sortKey="Ballif, Marie" sort="Ballif, Marie" uniqKey="Ballif M" first="Marie" last="Ballif">Marie Ballif</name></author><author><name sortKey="Fenner, Lukas" sort="Fenner, Lukas" uniqKey="Fenner L" first="Lukas" last="Fenner">Lukas Fenner</name></author><author><name sortKey="Pettit, April C" sort="Pettit, April C" uniqKey="Pettit A" first="April C" last="Pettit">April C. Pettit</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa South of the Sahara (epidemiology)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Antitubercular Agents (therapeutic use)</term><term>Asia, Southeastern (epidemiology)</term><term>CD4 Lymphocyte Count</term><term>Child</term><term>Child, Preschool</term><term>Coinfection (drug therapy)</term><term>Coinfection (epidemiology)</term><term>Databases, Factual</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>Humans</term><term>Infant</term><term>Male</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Treatment Outcome</term><term>Tuberculosis (drug therapy)</term><term>Tuberculosis (epidemiology)</term><term>Viral Load</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique subsaharienne (épidémiologie)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Antituberculeux (usage thérapeutique)</term><term>Asie du Sud-Est (épidémiologie)</term><term>Bases de données factuelles</term><term>Charge virale</term><term>Co-infection (traitement médicamenteux)</term><term>Co-infection (épidémiologie)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (épidémiologie)</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Nourrisson</term><term>Numération des lymphocytes CD4</term><term>Organisation mondiale de la santé</term><term>Résultat thérapeutique</term><term>Tuberculose (traitement médicamenteux)</term><term>Tuberculose (épidémiologie)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Antitubercular Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Africa South of the Sahara</term><term>Asia, Southeastern</term><term>Coinfection</term><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term><term>Infections à VIH</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Antituberculeux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Afrique subsaharienne</term><term>Asie du Sud-Est</term><term>Co-infection</term><term>Infections à VIH</term><term>Tuberculose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>CD4 Lymphocyte Count</term><term>Child</term><term>Child, Preschool</term><term>Databases, Factual</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Proportional Hazards Models</term><term>Retrospective Studies</term><term>Treatment Outcome</term><term>Viral Load</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Bases de données factuelles</term><term>Charge virale</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Nourrisson</term><term>Numération des lymphocytes CD4</term><term>Organisation mondiale de la santé</term><term>Résultat thérapeutique</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Management of tuberculosis (TB) is challenging in HIV/TB-coinfected children. The World Health Organization recommends nucleic acid amplification tests for TB diagnosis, a 4-drug regimen including ethambutol during intensive phase (IP) of treatment, and initiation of antiretroviral therapy (ART) within 8 weeks of TB diagnosis. We investigated TB treatment outcomes by diagnostic modality, IP regimen, and ART status.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28234689</PMID><DateCreated><Year>2017</Year><Month>02</Month><Day>24</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation></Journal><ArticleTitle>Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network.</ArticleTitle><Pagination><MedlinePgn>156-163</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000001335</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Management of tuberculosis (TB) is challenging in HIV/TB-coinfected children. The World Health Organization recommends nucleic acid amplification tests for TB diagnosis, a 4-drug regimen including ethambutol during intensive phase (IP) of treatment, and initiation of antiretroviral therapy (ART) within 8 weeks of TB diagnosis. We investigated TB treatment outcomes by diagnostic modality, IP regimen, and ART status.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective cohort study among HIV/TB-coinfected children enrolled at the International Epidemiology Databases to Evaluate AIDS treatment sites from 2012 to 2014. We modeled TB outcome using multivariable logistic regression including diagnostic modality, IP regimen, and ART status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 386 HIV-infected children diagnosed with TB, 20% had microbiologic confirmation of TB, and 20% had unfavorable TB outcomes. During IP, 78% were treated with a 4-drug regimen. Thirty-one percent were receiving ART at the time of TB diagnosis, and 32% were started on ART within 8 weeks of TB diagnosis. Incidence of ART initiation within 8 weeks of TB diagnosis was higher for those with favorable TB outcomes (64%) compared with those with unfavorable outcomes (40%) (P = 0.04). Neither diagnostic modality (odds ratio 1.77; 95% confidence interval: 0.86 to 3.65) nor IP regimen (odds ratio 0.88; 95% confidence interval: 0.43 to 1.80) was associated with TB outcome.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In this multinational study of HIV/TB-coinfected children, many were not managed as per World Health Organization guidelines. Children with favorable TB outcomes initiated ART sooner than children with unfavorable outcomes. These findings highlight the importance of early ART for children with HIV/TB coinfection, and reinforce the need for implementation research to improve pediatric TB management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carlucci</LastName><ForeName>James G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>*Vanderbilt Institute for Global Health, Nashville, TN; †Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; ‡Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN; §Vanderbilt Tuberculosis Center, Nashville, TN; ‖Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ¶Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN; #Children's Hospital 1, Ho Chi Minh City, Vietnam; **University of Ghana School of Medicine and Dentistry, Accra, Ghana; ††Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Masaka Regional Referral Hospital, Masaka, Uganda; §§The Ohio State University, College of Public Health, Columbus, OH; ‖‖Department of Pediatrics, Baylor College of Medicine, Houston, TX; ¶¶Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa; ##Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; ***Swiss Tropical and Public Health Institute, Basel, Switzerland; †††University of Basel, Basel, Switzerland; and ‡‡‡Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blevins Peratikos</LastName><ForeName>Meridith</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kipp</LastName><ForeName>Aaron M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Lindegren</LastName><ForeName>Mary L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Quy T</ForeName><Initials>QT</Initials></Author><Author ValidYN="Y"><LastName>Renner</LastName><ForeName>Lorna</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Reubenson</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ssali</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yotebieng</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mandalakas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Mary-Ann</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Ballif</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fenner</LastName><ForeName>Lukas</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Pettit</LastName><ForeName>April C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><CollectiveName>International Epidemiology Databases to Evaluate AIDS (IeDEA) Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI096299</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AI104352</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI096186</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD060554</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L40 AI126474</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI069911</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI110527</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI069919</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI069907</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI069924</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>West Indian Med J. 2004 Oct;53(5):339-45</RefSource><PMID Version="1">15675501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Natl Health Stat Report. 2013 Feb 11;(63):1-3</RefSource><PMID Version="1">24992748</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2010 Apr 15;201(8):1113-4</RefSource><PMID Version="1">20214477</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biomed Inform. 2009 Apr;42(2):377-81</RefSource><PMID Version="1">18929686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2002 Aug;6(8):672-8</RefSource><PMID Version="1">12150478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2008 Aug;8(8):498-510</RefSource><PMID Version="1">18652996</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(12):e27919</RefSource><PMID Version="1">22205933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Jun 1;24(9):1341-9</RefSource><PMID Version="1">20559039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Infect Dis J. 2014 May;33(5):499-503</RefSource><PMID Version="1">24736441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2014 Jun;18(6):694-9</RefSource><PMID Version="1">24903941</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2015;20(2):225-33</RefSource><PMID Version="1">25279808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2007 Aug 15;196 Suppl 1:S76-85</RefSource><PMID Version="1">17624829</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2014;19 Suppl 3:31-7</RefSource><PMID Version="1">25310534</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEMS Microbiol Rev. 2011 Nov;35(6):1126-57</RefSource><PMID Version="1">21521247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2004 May;8(5):648-57</RefSource><PMID Version="1">15137549</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2015 Apr 1;211 Suppl 2:S21-8</RefSource><PMID Version="1">25765103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2007 Apr;11(4):370-80</RefSource><PMID Version="1">17394681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pediatric Infect Dis Soc. 2015 Mar;4(1):30-8</RefSource><PMID Version="1">26407355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 May 22;10(5):e0127645</RefSource><PMID Version="1">26000446</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2014 Sep;18(9):1074-83</RefSource><PMID Version="1">25189555</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatr Pulmonol. 2016 Feb;51(2):157-64</RefSource><PMID Version="1">26073306</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Ther. 2016 May 12;13:22</RefSource><PMID Version="1">27182275</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2003 May 12;163(9):1009-21</RefSource><PMID Version="1">12742798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010 Oct 15;5(10):e13414</RefSource><PMID Version="1">20976211</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14(6):560-70</RefSource><PMID Version="1">26289343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2016 Nov;20(11):1448-1456</RefSource><PMID Version="1">27776584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2015 May 1;181(9):714-22</RefSource><PMID Version="1">25787266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int AIDS Soc. 2011 Jul 06;14 Suppl 1:S4</RefSource><PMID Version="1">21967844</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2007 Sep;11(9):965-71</RefSource><PMID Version="1">17705973</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet HIV. 2015 Mar 1;2(3):e107-e116</RefSource><PMID Version="1">26120593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Epidemiol. 2012 Oct;41(5):1256-64</RefSource><PMID Version="1">21593078</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pediatrics. 2006 Nov;118(5):e1350-9</RefSource><PMID Version="1">17079536</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet HIV. 2015 Mar;2(3):e107-16</RefSource><PMID Version="1">26424542</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2010 Aug;54(5):524-32</RefSource><PMID Version="1">20588185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharm Policy Pract. 2014 Apr 22;7:3</RefSource><PMID Version="1">25848543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Respir Med. 2015 Jun;3(6):451-61</RefSource><PMID Version="1">25812968</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:61-8</RefSource><PMID Version="1">26564545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):e67-75</RefSource><PMID Version="1">24977471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2014 Apr 24;28(7):1041-8</RefSource><PMID Version="1">24463393</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017954" MajorTopicYN="N">Africa South of the Sahara</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001210" MajorTopicYN="N">Asia, Southeastern</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28234689</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000001335</ArticleId><ArticleId IdType="pmc">PMC5429189</ArticleId><ArticleId IdType="mid">NIHMS851815</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000296 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000296 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28234689
|texte= Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28234689" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |